PetCaseFinder

Peer-reviewed veterinary case report

Does GnRH hormone test change prostate enzyme levels in dogs

By Ferré-Dolcet, Lluis et al.·Published in Reproduction in domestic animals = Zuchthygiene·2023·Clinica Veterinaria San Marco, Italy·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Effect of the GnRH stimulation test on Canine Prostatic-Specific Esterase (CPSE).

Species:
dog
Drinking & peeingDogs

Plain-English summary

A group of 28 intact male dogs were tested for fertility issues and prostate health using a hormone stimulation test. The dogs underwent a clinical and ultrasound examination of their prostate before and after receiving a hormone injection. While the hormone increased testosterone levels in all dogs, it did not significantly change the levels of a prostate-specific enzyme (CPSE) in most dogs. However, in about 15% of the dogs, the CPSE levels were high enough to suggest a prostate condition called benign prostatic hyperplasia (BPH). This study suggests that CPSE levels should not be measured after this hormone test, as it could lead to misleading results.

People also search for: dog prostate problems · benign prostatic hyperplasia in dogs · male dog fertility test

Abstract

The gonadotropin-releasing hormone (GnRH) stimulation test is used to investigate testicular production of testosterone (T) when performing a breeding soundness examination. In male dogs with fertility problems, the prostate should also be investigated as prostatic conditions may frequently lower semen quality. Serum concentrations of canine prostatic-specific esterase (CPSE) increase in dogs with benign prostatic hyperplasia (BPH). When performing a breeding soundness examination in a male dog, GnRH administration is frequently done at the beginning of the process and then both T and CPSE are assayed on the same serum sample collected 1 h following the GnRH injection. The aim of this study was to assess whether or not the administration of GnRH may alter CPSE concentrations in dogs with a healthy prostate. Twenty-eight client-owned intact adult male dogs were included in the study. Following a 7-day sexual rest all male dogs underwent a clinical examination and an ultrasonographic examination of the prostatic gland. Prostatic size and parenchyma of every tested dog were evaluated by ultrasonography to assess prostatic conditions. Two different GnRH stimulation protocols were used, A = gonadorelin 50μg/dog SC (n = 15) and B = buserelin 0.12 μg/kg IV (n = 13). T and CPSE concentrations were measured before and 1 h after GnRH administration by a laser-induced fluorescence analysis. Buserelin and gonadorelin were equally effective in causing a significant increase in serum T concentrations in the post GnRH sample. When considering the 28 dogs together, CPSE concentrations did not change following the stimulation test with either GnRH compound; however, in 4/28 cases, the post GnRH value was markedly increased to values compatible with a diagnosis of BPH. There was no difference in the action of buserelin or gonadorelin in causing an increase in serum T concentrations. CPSE secretion was increased in approximately 15% of dogs treated with either buserelin or gonadorelin. Therefore, whenever performing diagnostic testing in intact male dogs, CPSE should not be assayed on a post-GnRH serum sample.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37337834/